Side-by-side earnings comparison across financial stats, AI summaries, management guidance, risks, quotes, and accountability signals.
BPCL reported a stellar Q1 FY24 with consolidated PAT of INR 10,644 crore, its highest ever, driven by record refinery throughput at 115% capacity utilization and strong marketing volume growth of ~8% YoY.
Read Bharat Petroleum Corporation analysis →Divis Laboratories reported a consolidated total income of INR 1,859 crore for Q1 FY24, down from INR 2,343 crore in the same quarter last year, reflecting the absence of COVID-related demand and ongoing pricing pressures in generics.
Read Divislab analysis →BPCL reported a stellar Q1 FY24 with consolidated PAT of INR 10,644 crore, its highest ever, driven by record refinery throughput at 115% capacity utilization and strong marketing volume growth of ~8% YoY. Refinery GRM stood at $12.64/bbl, down sequentially due to weaker cracks, but Russian crude discounts provided a tailwind. Marketing margins improved as LPG under-recoveries were fully recouped. Management guided for INR 10,000 crore capex in FY24, with a larger INR 1.5 lakh crore five-year plan focused on petchem expansion at Bina (2.2 MTPA by 2028) and energy transition. A rights issue of INR 18,000 crore was approved to fund net-zero and energy security goals. Key risk: crude price volatility and potential narrowing of Russian crude discounts could pressure refining margins.
Divis Laboratories reported a consolidated total income of INR 1,859 crore for Q1 FY24, down from INR 2,343 crore in the same quarter last year, reflecting the absence of COVID-related demand and ongoing pricing pressures in generics. PAT stood at INR 66 crore, impacted by lower sales and forex gains. Management highlighted easing raw material costs and logistics, with material consumption falling to 39% of sales. The custom synthesis segment (40% of mix) is progressing well with phase II/III projects and two large commercial projects ramping up. Contrast media and Sartans are key growth drivers, with MRI contrast media validation expected by FY24-end. Unit III greenfield project is on track with INR 1,500 crore initial investment, expected to contribute by mid-FY25. Management guided for a steady-state EBITDA margin of 35-40% and double-digit revenue growth over the medium term, excluding one-offs. Key risks include sustained pricing pressure in US/European generics and potential raw material volatility.
Record quarterly throughput at 115% capacity utilization across all refineries.
Sequential decline due to weaker fuel cracks; Russian crude partially offset.
Part of plan to add 1,000 new outlets in FY24; total network expanding.
BPCL aims to convert all retail outlets into energy stations with EV charging.
Consolidated total income for Q1 FY24, down from INR 2,343 Cr in Q1 FY23.
Material consumption as a percentage of sales revenue, down from 42% in Q4 FY23.
Revenue split between generics (60%) and custom synthesis (40%) for the quarter.
Cash and cash equivalents as of March 31, 2023.
Management expects to spend INR 10,000 crore in capital expenditure during FY24, with INR 1,464 crore spent in Q1.
Management guidance capexBPCL plans to add approximately 1,000 new retail outlets during FY24; 111 were added in Q1.
Management guidance expansionBPCL aims to add another 500 CNG stations at existing retail outlets by the end of FY24.
Management guidance expansionA large petrochemical complex with 2.2 MTPA capacity and refinery expansion to 11 MMTPA is planned, with commissioning by 2028.
Management guidance growthManagement expects EBITDA margins to stabilize in the 35-40% range over the long term, excluding COVID-related distortions.
Management guidance marginsManagement anticipates double-digit revenue growth going forward, driven by custom synthesis, contrast media, and Sartans.
Management guidance revenueThe Unit III project in Kakinada, with an initial investment of INR 1,500 crore, is expected to start commercial production by mid-2025.
Management guidance expansionValidation for some MRI contrast media products is expected to be completed by the end of the current financial year, enabling customer sampling.
Management guidance growthManagement noted that crude prices have risen to $82-83/bbl and Russian crude discounts have narrowed sequentially, which could pressure refining margins.
high · management_commentaryManagement acknowledged that if Russian crude prices cross $60/bbl, payment issues may arise, though more banks are now willing to settle.
medium · analyst_questionThe Mozambique LNG project remains under force majeure; management expects work to restart in 1-2 quarters but cost overruns are likely.
medium · analyst_questionAnalyst questioned whether elevated capex plans (INR 1.5 lakh crore over 5 years) could impact dividend payouts; management reaffirmed 30% payout policy.
low · analyst_questionManagement acknowledged potential impact of price pressures in US and European markets on operating margins, though they remain optimistic.
medium · management_commentaryWhile raw material prices are currently softening, management noted that price variations could recur, especially for solvents like acetonitrile.
medium · analyst_questionCustom synthesis growth depends on customer approvals and project timelines, which are uncertain and not quarter-to-quarter predictable.
medium · management_commentaryBPCL has registered highest ever quarterly EBITDA, highest ever profit after tax, excluding the exception items, and highest ever total equity during quarter one.
We have to wait and see how the crude prices will behave. If we feel the crude prices will stabilize at this level for a longer period of time, then we can take a call.
We see a stable, probably steady 35%-40%. I think that's what we can comfortably say.
Slow, steady, consistent, and debt-free. These are our models.
